A dose-response study of a live attenuated varicella-zoster virus (oka strain) vaccine administered to adults 55 years of age and older

Journal of Infectious Diseases

Volumn 178, Issue 5 SUPPL., 1998, Pages

  Berger, Rosemarie ^b   Trannoy, Emanuelle ^b   Holländer, Georges ^b   Bailleux, Fabrice ^b   Rudin, Christophe ^b   Creusvaux, Hervé ^a  

^a Pasteur Merieux Connaught Grp   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANTIBODY TITER; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

EID: 0031791733     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514265     Document Type: Conference Paper

References (13)

1. Gershon A, Silverstein S. Live, attenuated varicella vaccine for prevention of herpes zoster. Biologicals 1997;25:227-30.
2. Ragozzino MW, Melton LJ III, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310-6.
3. Berger R, Florent G, Just M Decrease of the lymphoproliferative response to varicella zoster virus antigen in the aged. Infect Immun 1981;32:24-7.
4. Berger R, Luescher D, Just M. Enhancement of varicella-zoster - specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 1984;149:647.
5. Levin M, Murray M, Rotbart H, Zerbe G, White CJ, Hayward AR. Immune response of elderly individuals to a live, attenuated varicella vaccine. J Infect Dis 1992;166:253-9.
6. Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune responses of elderly persons 4 years after receiving a live, attenuated varicella vaccine. J Infect Dis 1994;170:522-6.
7. Oxman MN, Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45:S41-6.
8. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospitals. Lancet 1974;2:1288-90.
9. LaRussa P, Lungu O, Gershon A, Steinberg SP, Silverstein S. Restriction fragment length polymorphism chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 1992;66:1016-20.
10. Fanget B, Françon A. A varicella vaccine stable at 5°C. Dev Biol Stand 1996;87:167-71.
11. Hayward AR, Zerbe GO, Levin MJ. Clinical application of responder cell frequency estimates with four years of follow-up. J Immunol Methods 1994;170:27-36.
12. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991;9:111-6.
13. Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis 1990;162:1049-54.